California Bids > Bid Detail

TECHNOLOGY/BUSINESS OPPORTUNITY Antibacterial Minerals: A geochemical approach to combating antibiotic resistance

Agency: ENERGY, DEPARTMENT OF
Level of Government: Federal
Category:
  • 99 - Miscellaneous
  • A - Research and development
Opps ID: NBD00159750219891710
Posted Date: Mar 8, 2023
Due Date: Mar 8, 2023
Solicitation No: IL-13445
Source: https://sam.gov/opp/80155b7836...
Follow
TECHNOLOGY/BUSINESS OPPORTUNITY Antibacterial Minerals: A geochemical approach to combating antibiotic resistance
Active
Contract Opportunity
Notice ID
IL-13445
Related Notice
Department/Ind. Agency
ENERGY, DEPARTMENT OF
Sub-tier
ENERGY, DEPARTMENT OF
Office
LLNS – DOE CONTRACTOR
General Information
  • Contract Opportunity Type: Special Notice (Original)
  • All Dates/Times are: (UTC-08:00) PACIFIC STANDARD TIME, LOS ANGELES, USA
  • Original Published Date: Mar 08, 2023 08:50 am PST
  • Original Response Date: Mar 08, 2023 09:00 am PST
  • Inactive Policy: Manual
  • Original Inactive Date: Apr 10, 2023
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code:
  • NAICS Code:
    • 325412 - Pharmaceutical Preparation Manufacturing
  • Place of Performance:
    Livermore , CA
    USA
Description

Opportunity:



Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to commercialize its antibacterial minerals.



Background:



The development of antibiotics heralded a revolution in the treatment of bacterial infection. However, the indiscriminate use of antibiotics has led to the emergence of antibiotic resistance. The U.S. currently spends $20 billion a year treating over 2 million antibiotic resistant infections that can withstand even the most potent antibiotics. The pathogens: Enterococcus faecium, Staphylococcus. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter (ESKAPE) represent the most common group of human pathogens that ‘escape’ the effects of antibiotics in clinical settings.



A resurgence of inquiry into alternative antibacterial mechanisms has emerged as human pathogens have evolved antibiotic resistance. Certain naturally occurring clays have been shown to harbor antimicrobial properties and kill antibiotic resistant bacteria. These clays have been proposed as a new paradigm for fighting the potentially devastating effects of the post antibiotic era. However, natural samples, by their inherent properties, exhibit variable antibacterial effectiveness and the synthesis of minerals with reproducible antibacterial activity is needed. The goal is to develop optimized synthetic versions of these clays that are more effective and reliable.



Description:



A new approach of developing synthetic antibacterial mineral assemblages can be used as an alternative treatment when traditional antibiotics fail in clinical and agricultural settings. Mineral mixtures can be synthesized with tunable metal release and reactive oxygen species generation that are capable of killing human pathogens and promoting wound healing. One of the key components in the natural antibacterial clays is their ability to release soluble metals. Studies on natural antibacterial clay deposits have implicated Fe-sulfides and expandable clays, such as smectite, in the antibacterial mechanism. These minerals are thought to work by buffering solution pH and redox potential and maintaining hydration, while providing extended release of Fe2+, Al3+ and reactive oxygen species (ROS).



The synthesis of clay mineral Fe-sulfide composites (F-Hectorite and Pyrite) that mimic the antibacterial activity of natural samples has been shown to be successful. The synthetic mineral mixtures were tested for antibacterial activity against E. coli and S. epidermidis at 100, 50 and 25 mg/ml mineral concentrations. The 50 mg/ml dose of minerals effectively killed E. coli after 24 hours while maintaining Fe2+ and H2O2 release. A 25 mg/ml dose of minerals killed S. epidermidis after 24 hours. The mineral mixtures maintain an extended release of Fe2+ (1-2 mM) and H2O2 (100-300 µM) over 24 hours while increasing the redox potential of the hydrated mineral suspension to an Eh > 400 mV. The hydrated minerals buffer the pH of the hydrated poultice to pH 4.5 to 5.3 over 24 hours depending on the dose. The potency of the mineral mixtures can be tuned by varying the wt. % of pyrite or by increasing the concentration of FeSO4 in the exchange solution. The starting pH can be adjusted to pH



Advantages/Benefits:



These synthetic antibacterial minerals eliminate any chemical impurities found in natural samples. Furthermore, the reactivity, Fe2+ and H2O2 release can be tuned to increase or decrease the redox reactions that result in the generation of ROS for various applications in human health, wound care, livestock and municipal biosolids treatment.



The synthetic antibacterial minerals also address many shortcomings of current approaches. They can stabilize aqueous environments to pH 400 mV) relative to chronic wound environments. The synthetic minerals can maintain the low pH for many hours due to their buffering capacity and continued release of H+ during pyrite oxidation.



The application of synthetic antibacterial minerals to wounds may function in wound healing by lowering the pH of a chronic wound from alkaline conditions allowing the release of oxygen from hemoglobin while potentially generating reactive oxygen species resulting in a burst of ROS similar to those utilized by macrophages.



Potential Applications:




  • Wound care (e.g. dressings, topical treatment for infections)

  • Cosmetic and personal care products (mineral masks, acne treatment)

  • Animal health (treatment for topical or gastrointestinal infections)



Development Status:



U.S. Patent Application Publication No. 2022/0000912 Synthetic antimicrobial mineral compositions, methods of making and using same published 1/6/2022



Current stage of technology development: TRL-2 (3/2023)



LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information.



Please visit the IPO website at https://ipo.llnl.gov/resources for more information on working with LLNL and the industrial partnering and technology transfer process.





Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's Antibacterial Minerals should provide a written statement of interest, which includes the following:



1. Company Name and address.



2. The name, address, and telephone number of a point of contact.



3. A description of corporate expertise and/or facilities relevant to commercializing this technology.





Written responses should be directed to:



Lawrence Livermore National Laboratory



Innovation and Partnerships Office



P.O. Box 808, L-779



Livermore, CA 94551-0808



Attention: IL-13445





Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's Antibacterial Minerals.


Attachments/Links
Contact Information
Contracting Office Address
  • 7000 East Avenue
  • Livermore , CA 94551
  • USA
Primary Point of Contact
Secondary Point of Contact
History
  • Mar 08, 2023 08:50 am PSTSpecial Notice (Original)

TRY FOR FREE

Not a USAOPPS Member Yet?

Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.

Start Free Trial Today >